LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5604.69M
Enterprise Value 3718.54M
Trailing P/E N/A
Forward P/E 1-10.16
PEG Ratio (5 yr expected) 1-0.42
Price/Sales (ttm)12.85
Price/Book (mrq)N/A
Enterprise Value/Revenue 315.27
Enterprise Value/EBITDA 6-8.85

Trading Information

Stock Price History

Beta (3Y Monthly) 1.45
52-Week Change 3-54.87%
S&P500 52-Week Change 37.40%
52 Week High 313.31
52 Week Low 34.25
50-Day Moving Average 35.99
200-Day Moving Average 36.13

Share Statistics

Avg Vol (3 month) 3494.18k
Avg Vol (10 day) 3308.34k
Shares Outstanding 5106.27M
Float 105.82M
% Held by Insiders 10.40%
% Held by Institutions 1101.30%
Shares Short (Jun 14, 2019) 48.27M
Short Ratio (Jun 14, 2019) 425.34
Short % of Float (Jun 14, 2019) 431.48%
Short % of Shares Outstanding (Jun 14, 2019) 47.78%
Shares Short (prior month May 15, 2019) 410.77M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 27/1
Last Split Date 3May 21, 2015

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -213.65%
Operating Margin (ttm)-176.48%

Management Effectiveness

Return on Assets (ttm)-16.08%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)47.05M
Revenue Per Share (ttm)0.44
Quarterly Revenue Growth (yoy)-63.70%
Gross Profit (ttm)-39.52M
EBITDA -81.18M
Net Income Avi to Common (ttm)-100.53M
Diluted EPS (ttm)-0.95
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)133.15M
Total Cash Per Share (mrq)1.25
Total Debt (mrq)246.99M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)5.20
Book Value Per Share (mrq)-0.43

Cash Flow Statement

Operating Cash Flow (ttm)-127.45M
Levered Free Cash Flow (ttm)-111.03M